AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
High relapse rate for ovarian cancer drives demand for expanded therapeutic options, according to Frost & Sullivan.
2002 MAR 14 - (NewsRx.com & NewsRx.net) -- The high relapse rate in ovarian cancer patients will continue to drive demand for a wider range of therapeutic options, according to new analysis released by Frost & Sullivan.
Although chemotherapy is effective in achieving remission in most patients, the result often lasts less than two years. Further chemotherapy provides only limited success.
Given the prevalence of ovarian cancer in the U.S., markets for new therapeutics are sure to reward effective treatments.
New analysis from Frost & Sullivan, "U.S. Emerging Ovarian Cancer Therapeutics Markets," reveals markets for chemotherapy agents generated revenues totaling $702 million in 2000. Market revenues will grow to $1.7 billion in 2008, driven largely by the anticipated introduction of monoclonal antibodies, and other immunotherapeutics.
"The expiration of patents for a number of leading chemotherapeutic drugs over the past year and in the coming five years will open the door for generic competition and threaten the profitability of established ...
- Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay...
- Press release article from: PR Newswire September 16, 2008 700+ words
...currently available treatments for ovarian cancer. The new test will be powered by Key...physicians will be able to quickly direct ovarian cancer patients towards appropriate lines...of cancer death in women. In 2008, ovarian cancer will be diagnosed in more than 20...
- OXiGENE Reports Positive Results in Phase 2 Study of ZYBRESTAT(TM) in...
- Press release article from: Business Wire December 31, 2007 700+ words
...for Stage 1 of an ongoing Phase 2 ovarian cancer clinical trial. The clinical trial...with advanced, platinum-resistant ovarian cancer, a refractory form of ovarian cancer for which therapeutic options are limited. Having met the Stage...
- Aflibercept: strong Ph II data in ovarian cancer.(Clinical report)
- Newspaper article from: Pharma Marketletter June 2, 2008 700+ words
...aflibercept in advanced ovarian cancer patients, a population for whom few therapeutic options are available. In...women with advanced ovarian cancer who were treated with...patients with advanced ovarian cancer and SMA treated with...
- Seattle Genetics Initiates Phase II Clinical Trial of SGN-15 in Advanced...
- Press release article from: Business Wire August 20, 2002 700+ words
...compare results of ovarian cancer patients treated...study in advanced ovarian cancer, a stage of the disease with limited therapeutic options," added Amy P...malignancies. About Ovarian Cancer The American Cancer...
- Investigational drug shows promise in ovarian cancer.
- Newspaper article from: Clinical Trials Week September 29, 2008 700+ words
...investigating the drug for ovarian cancer will now go ahead. "The majority of patients with ovarian cancer will have advanced disease...pazopanib to ensure new therapeutic options for patients with ovarian cancer." Keywords: Chemotherapy...
- CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Ovarian...
- Press release article from: PR Newswire September 13, 2005 700+ words
...About Ovarian Cancer Ovarian cancer is the fourth leading...22,000 new cases of ovarian cancer will be diagnosed in...Despite advances in therapeutic options, the mortality rate for ovarian cancer has not improved significantly...
- OXiGENE's Zybrestat achieves endpoints in ovarian cancer.
- Newspaper article from: Pharma Marketletter January 7, 2008 700+ words
...for Stage 1 of an ongoing Phase II ovarian cancer clinical trial. The study utilized...with advanced, platinum-resistant ovarian cancer, a refractory form of the disease for which therapeutic options are limited. Having met the Stage...
- Gemzar(R) Combination Therapy Receives European Regulatory Approvals for...
- Press release article from: PR Newswire July 29, 2004 700+ words
...women with recurrent ovarian cancer. "We are pleased...women with recurrent ovarian cancer. The consistent...offer new innovative therapeutic options." About the Study...to worsen. Many ovarian cancer patients will receive...
Source: HighBeam Research, High relapse rate for ovarian cancer drives demand for expanded...